Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion
Condition(s):Malignant Ascites; Malignant Pleural EffusionLast Updated:July 15, 2013Terminated
Hide Studies Not Open or Pending
Condition(s):Malignant Ascites; Malignant Pleural EffusionLast Updated:July 15, 2013Terminated
Condition(s):Sarcoma, Alveolar Soft PartLast Updated:March 12, 2024Active, not recruiting
Condition(s):Solid TumorsLast Updated:January 10, 2024Active, not recruiting
Condition(s):Ovarian CancerLast Updated:September 23, 2015Unknown status
Condition(s):Ovarian CancerLast Updated:June 12, 2018Completed
Condition(s):CancerLast Updated:November 1, 2012Completed
Condition(s):Renal Cell CarcinomaLast Updated:February 2, 2017Completed
Condition(s):Cervical CancerLast Updated:July 27, 2020Unknown status
Condition(s):Uveal Melanoma; Metastatic CancerLast Updated:June 2, 2020Withdrawn
Condition(s):Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus CarcinomaLast Updated:August 8, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.